The FDA has accepted applications for three new indications for bimekizumab-bkzx, a humanized interleukin (IL) 17A and IL-17F antagonist: psoriatic arthritis, non-radiographic axial spondyloarthritis and ankylosing spondylitis.
Search results for: psoriasis
Pharmacokinetic Modeling & Efficacy Extrapolation: FDA Takes New Approaches to Drug Approvals
An array of new and expanded indications of therapeutics for rheumatic disease last year relied on pharmacokinetic modeling for intravenous dosing and efficacy extrapolation for pediatric populations.
Insight into the FDA Approval of Ustekinumab Biosimilar
In late October, the FDA approved the first biosimilar to ustekinumab to treat patients with psoriasis, psoriatic arthritis and other conditions. Ustekinumab-auub is expected to be available in the U.S. by 2025.
Skin & Joints: Experts Discuss Advances in PsA
SAN DIEGO—The understanding of the microenvironment in which immune cells interact with stromal cells in the synovium of psoriatic arthritis (PsA) and rheumatoid arthritis (RA) is deepening, potentially giving clues for treatments. As this understanding improves, so does the appreciation for its astounding complexity, an expert said here in a session at ACR Convergence, which…
Where Viral Infections Meet Rheumatic Disease
SAN DIEGO—Viral infections are a common cause of acute arthritis and, in general, tend to be short lived and are not usually associated with significant articular inflammation. Due to the prevalence of various viral infections across the globe, any patient with signs of early inflammatory arthritis (i.e., symptoms that have not yet lasted six weeks) should be evaluated for a possible infectious etiology, said Dr. Leonard Calabrese in the Review Course at ACR Convergence 2023.
The Heterogeneity of Psoriatic Arthritis
SAN DIEGO—Differences between psoriatic arthritis and rheumatoid arthritis highlight the need for the development of imaging modalities, laboratory tests and other biomarkers that are explored and validated specifically for PsA to advance the goal of personalized or precision medicine. In this article, expert David S. Pisetsky, MD, PhD, explores the top research in psoriatic arthritis presented at ACR Convergence 2023.
More Than Meets the Eye
SAN DIEGO—In recent years, the recognition of nr-axSpa has helped identify the cause of back pain in many patients previously without a diagnosis. However, questions remain about how to avoid under- or over-diagnosing the condition. In the session titled, Pearls and Pitfalls in Diagnosing Non-Radiographic Axial Spondyloarthritis, several speakers provided high-yield insights on this topic. Diagnostic challenges, imaging options and mimics to watch for were among the specific points of discussion.
From Basic Science to Clinical Treatments: An Update on PsA
Dr. Christopher Ritchlin provided insights into the underlying mechanisms of the immune system that promote disease activity in patients with psoriatic arthritis (PsA), the latest research on how to optimize therapy for PsA and more.
Concerning the Back: Updates in AS & nr-axSpA
During the 19th Annual Johns Hopkins Advances in the Diagnosis and Treatment of the Rheumatic Diseases Symposium, Dr. Atul Deodhar provided an overview on axial spondyloarthritis (axSpA) and non-radiographic axSpA, with helpful insights into the diagnosis and care of patients with these conditions.
Why Mental Health Screening Is Essential for Patients with Psoriatic Disease
Research suggests that patients with psoriasis and psoriatic arthritis (PsA) have a greater risk of depression, anxiety and, in some cases, substance abuse and dependence than the general population, yet symptoms often go unrecognized and untreated by medical professionals. Both psoriasis and PsA are associated with depression, with up to 30% of patients in either…
- « Previous Page
- 1
- …
- 9
- 10
- 11
- 12
- 13
- …
- 55
- Next Page »